- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Astrazeneca Share News (AZN)
Share News for Astrazeneca (AZN)
| Share Price: 3,241.00 | Bid: 3,237.00 | Ask: 3,238.50 | Change: 0.00 (0.00%) |  | ||||||
| ||||||||||
BRIEF-AstraZeneca says Bristol-Myers completes purchase of Amylin
Thu, 9th Aug 2012 13:12
LONDON, Aug 9 (Reuters) - AstraZeneca PLC:
* Informed Bristol Myers Squibb-of intention t
additional governance rights
* Upon exercise of the option an additional payment of $135 million will be
made to Bristol Myers Squibb-
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
LONDON, Aug 9 (Reuters) - AstraZeneca PLC:
* Informed Bristol Myers Squibb-of intention t
o exercise option to buy certain
additional governance rights
* Upon exercise of the option an additional payment of $135 million will be
made to Bristol Myers Squibb-
((London Equities Newsroom; +44 20 7542 7717))
(For more news, please click here)
COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
UPDATE 2-Astra, Bristol diabetes drug disappoints in key test
* Onglyza fails to show cardiovascular benefit in study* Positive results might have added $1 bln to peak sales* Drug achieves non-inferiority goal ve[Yesterday 16:09]
AstraZeneca, Bristol diabetes drug fails to show heart benefit
LONDON, June 19 (Reuters) - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study.The co[Yesterday 06:15]
INTERVIEW-AstraZeneca turnaround is 3-4 year journey, says CEO
* Drugmaker revamping R&D, stepping up targeted acquisitions* Some scientists to move to Cambridge before 2016* Results of Onglyza diabetes drug trial[Tue 16:46]
INTERVIEW-AstraZeneca turnaround is 3-4 year journey, says CEO
LONDON, June 18 (Reuters) - Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions[Tue 16:16]
REFILE-UPDATE 1-AstraZeneca picks site for new global home in Cambridge
* Cambridge Biomedical Campus to house new HQ and R&D centre* Some 2,000 jobs to be located on $500 million site by 2016* Move forms centrepiece of pl[Tue 09:25]
AstraZeneca picks its new home in Cambridge next to top hospital
LONDON, June 18 (Reuters) - AstraZeneca has chosen a science park in Cambridge, England, next to the world-renowned Addenbrooke's Hospital, as its ne[Tue 07:06]
AstraZeneca taps outside experts to screen cancer compounds
LONDON, June 14 (Reuters) - British drugmaker AstraZeneca is deepening its collaboration with academia by roping in more outside researchers to help[13 Jun '13]
Drugmakers to cooperate in safety review of diabetes drugs
By Bill BerkrotNEW YORK, June 12 (Reuters) - Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns o[12 Jun '13]
